Equillium (EQ) Market Update
Trading Performance: Equillium shares increased 2.9 % during the 24‑hour period ending at 10:38 PM Central Europe on Friday, 23 November 2026. The current trading price is USD 1.23 per share on major exchanges.
Supply and Market Capitalisation: Outstanding shares: 63.2 million. Market capitalisation: USD 90 million.
Volume and Recent Trends: Trading volume in the last 24 hours: USD 628.4 k. Since the end of the previous month, the share price has fallen 26.42 %.
Technical Indicators: 200‑day simple moving average: USD 2.07. 52‑week high: USD 3.54 (30 June 2026). 52‑week low: USD 0.76 (14 November 2025).
Related Corporate News
- CreditAccess Grameen Limited released unaudited results for the first half of fiscal year 2026‑27. The company reported higher pre‑tax and post‑tax profits, citing an improved credit cost profile and better collection efficiency. Updated guidance for the remaining half‑year raises expectations for return on assets and equity. The board appointed Sharp & Tannan, Chartered Accountants, as joint statutory auditors, replacing the previous firm. The unaudited results were issued via press release and board‑meeting notices.
24‑Hour Performance of Peer Stocks
| Symbol | Price Change | Current Price | Market Capitalisation |
|---|---|---|---|
| CBUS | –0.71 % | USD 1.41 | USD 107.8 million |
| PBHC | +2.68 % | USD 16.72 | USD 105.2 million |
| ETS | +4.85 % | USD 2.41 | USD 105.2 million |
| DERM | –8.05 % | USD 5.02 | USD 106.7 million |
| UNCY | +1.84 % | USD 3.89 | USD 107.8 million |
- Unicycive Therapeutics (UNCY) – A clinical‑stage biotechnology company focused on kidney disease. The firm received FDA approval to resubmit its New Drug Application for oxylanthanum carbonate (OLC), an investigational oral phosphate binder for hyperphosphatemia in dialysis patients. The resubmission incorporates new chemistry, manufacturing, and controls data from a third‑party manufacturer. The FDA has designated the resubmission as a Class II submission, with a six‑month review period and a target action date in late March 2027. No concerns were raised about preclinical or clinical data in the original submission. Unicycive plans to pursue regulatory approval through the 505(b)(2) pathway, aiming to shorten the approval timeline if the FDA’s inspection outcomes are favorable.
Company Overview – Equillium
Equillium Inc. is a biotechnology company that develops products for autoimmune and inflammatory disorders. The company serves patients in the state of California. Equillium trades on the Nasdaq stock exchange under the ticker EQ. The IPO date was 11 October 2018. The company’s website is www.equilliumbio.com .
